Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVIVE HERoes: T-DXd in ctDNA+ Early Breast Cancer
NCT06643585Phase 3Recruiting
- Sponsor
- Prof. Wolfgang Janni
- Start
- Apr 2025
- Primary completion
- Apr 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Prof. Wolfgang Janni. Primary endpoint: ctDNA clearance rate at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06643585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643585.